Treatment Guidelines for Axial Spondyloarthritis

Sonam Kiwalkar; Atul Deodhar; Joachim Sieper

doi:10.1016/B978-0-323-56800-5.00016-3

Treatment Guidelines for Axial Spondyloarthritis

Sonam Kiwalkar, Atul Deodhar, Joachim Sieper

Arthritis and Rheumatic Diseases

Research output: Chapter in Book/Report/Conference proceeding › Chapter

2 Scopus citations

Abstract

As novel therapeutic agents become available for the treatment of axial spondyloarthritis (axSpA), management decisions in daily practice become complicated. Moreover, medication approval and cost vary widely by geography. Treatment recommendations for management of axSpA are therefore developed by many national societies. The two most widely publicized are treatment recommendations developed by the Assessment of SpondyloArthritis International Society/European League against Rheumatism (ASAS-EULAR), (Van Der Heijde et al., 2017)¹ and by the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) (Ward et al., 2016). Both propose a step-up approach for nonpharmacologic and pharmacologic treatments. This chapter addresses the science of development of treatment recommendations, similarities and differences between these two sets of recommendations and explores their implications on patient management.

Original language	English (US)
Title of host publication	Axial Spondyloarthritis
Publisher	Elsevier
Pages	243-258
Number of pages	16
ISBN (Electronic)	9780323568005
DOIs	https://doi.org/10.1016/B978-0-323-56800-5.00016-3
State	Published - Jan 1 2019

Keywords

Ankylosing spondylitis
Axial spondyloarthritis
Treatment guidelines
Treatment recommendations

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-323-56800-5.00016-3

Cite this

@inbook{b9e4eea28fdc45fdbc52e6c86a2b11dc,

title = "Treatment Guidelines for Axial Spondyloarthritis",

abstract = "As novel therapeutic agents become available for the treatment of axial spondyloarthritis (axSpA), management decisions in daily practice become complicated. Moreover, medication approval and cost vary widely by geography. Treatment recommendations for management of axSpA are therefore developed by many national societies. The two most widely publicized are treatment recommendations developed by the Assessment of SpondyloArthritis International Society/European League against Rheumatism (ASAS-EULAR), (Van Der Heijde et al., 2017)1 and by the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) (Ward et al., 2016). Both propose a step-up approach for nonpharmacologic and pharmacologic treatments. This chapter addresses the science of development of treatment recommendations, similarities and differences between these two sets of recommendations and explores their implications on patient management.",

keywords = "Ankylosing spondylitis, Axial spondyloarthritis, Treatment guidelines, Treatment recommendations",

author = "Sonam Kiwalkar and Atul Deodhar and Joachim Sieper",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-56800-5.00016-3",

language = "English (US)",

pages = "243--258",

booktitle = "Axial Spondyloarthritis",

publisher = "Elsevier",

}

TY - CHAP

T1 - Treatment Guidelines for Axial Spondyloarthritis

AU - Kiwalkar, Sonam

AU - Deodhar, Atul

AU - Sieper, Joachim

PY - 2019/1/1

Y1 - 2019/1/1

N2 - As novel therapeutic agents become available for the treatment of axial spondyloarthritis (axSpA), management decisions in daily practice become complicated. Moreover, medication approval and cost vary widely by geography. Treatment recommendations for management of axSpA are therefore developed by many national societies. The two most widely publicized are treatment recommendations developed by the Assessment of SpondyloArthritis International Society/European League against Rheumatism (ASAS-EULAR), (Van Der Heijde et al., 2017)1 and by the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) (Ward et al., 2016). Both propose a step-up approach for nonpharmacologic and pharmacologic treatments. This chapter addresses the science of development of treatment recommendations, similarities and differences between these two sets of recommendations and explores their implications on patient management.

AB - As novel therapeutic agents become available for the treatment of axial spondyloarthritis (axSpA), management decisions in daily practice become complicated. Moreover, medication approval and cost vary widely by geography. Treatment recommendations for management of axSpA are therefore developed by many national societies. The two most widely publicized are treatment recommendations developed by the Assessment of SpondyloArthritis International Society/European League against Rheumatism (ASAS-EULAR), (Van Der Heijde et al., 2017)1 and by the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) (Ward et al., 2016). Both propose a step-up approach for nonpharmacologic and pharmacologic treatments. This chapter addresses the science of development of treatment recommendations, similarities and differences between these two sets of recommendations and explores their implications on patient management.

KW - Ankylosing spondylitis

KW - Axial spondyloarthritis

KW - Treatment guidelines

KW - Treatment recommendations

UR - http://www.scopus.com/inward/record.url?scp=85099284951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099284951&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-56800-5.00016-3

DO - 10.1016/B978-0-323-56800-5.00016-3

M3 - Chapter

AN - SCOPUS:85099284951

SP - 243

EP - 258

BT - Axial Spondyloarthritis

PB - Elsevier

ER -

Treatment Guidelines for Axial Spondyloarthritis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this